China's drug regulator approved the marketing application for oseltamivir phosphate produced by Shijiazhuang Yiling Pharmaceutical (SHE:002603) subsidiary Wanyang Hengshui Pharmaceutical, according to a Friday stock disclosure in Shenzhen.
The drug helps treat influenza A and B.